Recurring Breast Cancer Differentiated by Blood Test
|
By LabMedica International staff writers Posted on 17 Apr 2012 |
|
A newly introduced blood test is twice as sensitive and can detect breast cancer recurrence a full year earlier than current blood tests.
Currently available blood tests are not very sensitive and the best-known test for a biological "marker" protein, misses many cases of recurrence and detects them late, often after symptoms surface.
A team of scientists at Purdue University (West Lafayette, IN, USA) analyzed many hundreds of "metabolites" in the blood of breast cancer survivors. Metabolites are small molecules, biological byproducts formed as the body's cells go about the business of life, and some are released into the bloodstream and urine. The markers are detected with an instrument called a mass spectrometer (MS), which is common in clinical laboratories.
These markers would be used in combination with results from breast carcinoma antigen CA 27.29 blood tests. The investigators have found that combining MS and nuclear magnetic resonance spectroscopy (NMR) methods improves the ability to perform global metabolite profiling, and has revealed a set of biomarkers that are very sensitive and specific for detecting early breast cancer recurrence. The derived metabolite profile is twice as sensitive as the CA 27.29 assay, and detects recurrence 12 months earlier. The profile has been ported to a single MS platform and validated using an independent set of approximately 100 patient samples.
Daniel Raftery, PhD, the team leader said, "We take both of those results together and roll those into the profile so that the score we generate is a combination of the CA value and our nine metabolites. If the score indicates that the cancer probably has returned, the patient would then likely undergo imaging tests to locate the tumor." Dr. Raftery hopes that the new test will become available later this year. In the meantime, the scientists are conducting another clinical study with the test. In the future, the test might be useful in the early detection of breast cancer, not just recurrences. A commercial company called Matrix-Bio (West Lafayette, IN, USA) has been set up to develop the assay. The results of the study were present at the 243rd National Meeting and Exposition of the American Chemical Society, held March 25-29, 2012, in San Diego, CA, USA.
Related Links:
Purdue University
Matrix-Bio
Currently available blood tests are not very sensitive and the best-known test for a biological "marker" protein, misses many cases of recurrence and detects them late, often after symptoms surface.
A team of scientists at Purdue University (West Lafayette, IN, USA) analyzed many hundreds of "metabolites" in the blood of breast cancer survivors. Metabolites are small molecules, biological byproducts formed as the body's cells go about the business of life, and some are released into the bloodstream and urine. The markers are detected with an instrument called a mass spectrometer (MS), which is common in clinical laboratories.
These markers would be used in combination with results from breast carcinoma antigen CA 27.29 blood tests. The investigators have found that combining MS and nuclear magnetic resonance spectroscopy (NMR) methods improves the ability to perform global metabolite profiling, and has revealed a set of biomarkers that are very sensitive and specific for detecting early breast cancer recurrence. The derived metabolite profile is twice as sensitive as the CA 27.29 assay, and detects recurrence 12 months earlier. The profile has been ported to a single MS platform and validated using an independent set of approximately 100 patient samples.
Daniel Raftery, PhD, the team leader said, "We take both of those results together and roll those into the profile so that the score we generate is a combination of the CA value and our nine metabolites. If the score indicates that the cancer probably has returned, the patient would then likely undergo imaging tests to locate the tumor." Dr. Raftery hopes that the new test will become available later this year. In the meantime, the scientists are conducting another clinical study with the test. In the future, the test might be useful in the early detection of breast cancer, not just recurrences. A commercial company called Matrix-Bio (West Lafayette, IN, USA) has been set up to develop the assay. The results of the study were present at the 243rd National Meeting and Exposition of the American Chemical Society, held March 25-29, 2012, in San Diego, CA, USA.
Related Links:
Purdue University
Matrix-Bio
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Electrolyte Analyzer
CBS-4000 (CBS-400)
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Molecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more
